Randomized phase III trial of paclitaxel plus topotecan versus topotecan plus cisplatin in recurrent or persistent cervical cancer stage IVb
Completed
- Conditions
- Advanced carcinoma of the cervix uteriCancerCervical cancer
- Registration Number
- ISRCTN77165120
- Lead Sponsor
- Institute for Women’s Health (Institut fuer Frauengesundheit GmbH) (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 326
Inclusion Criteria
Patients with progressive histologically confirmed carcinoma of the cervic uteri and measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST]) without treatment alternatives to chemotherapy
Exclusion Criteria
Bilateral hydronephrosis, central nervous system (CNS)-metastases or reduced general condition
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method